This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up

Sixty-seven percent of GA101-treated patients experience a serious side effect, including 34% reporting significant drops in white blood cell counts known as neutropenia. By comparison, the rate of serious adverse events associated with chemotherapy was 41 percent, including 15% occurrence of neutropenia.

These are the data Roche filed with FDA seeking GA101's approval but investors are more interested in how GA101 stacks up against Rituxan. The second stage of the phase III study is not ready for a final analysis, but preliminary data released Wednesday shows GA101 might be a better drug.

CLL patients treated with Rituxan reported a median PFS of 15.7 months, which is numerically inferior to the 23-month median PFS for GA101. The Rituxan data will change, however, as the study matures. Roche expects to have more definitive results from the second stage of the study later this year.

New CLL therapies are also being developed by Pharmacyclics (PCYC) (ibrutinib) and Gilead Sciences (GILD - Get Report) (idelalisib.)

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RHHBY $31.65 -0.63%
GILD $87.25 -2.00%
PCYC $0.00 0.00%
AAPL $93.95 0.33%
FB $117.82 -0.63%


Chart of I:DJI
DOW 17,702.21 -188.95 -1.06%
S&P 500 2,058.19 -23.24 -1.12%
NASDAQ 4,759.58 -58.0140 -1.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs